Dong Xie
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial.
Journal: BMC infectious diseases
Published: December 11, 2025
Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders.
Journal: Frontiers in cellular and infection microbiology
Published: March 08, 2024
Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: April 19, 2023
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2.
Journal: Antiviral research
Published: July 24, 2022
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.
Journal: Chinese medical journal
Published: November 30, 2020
Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients.
Journal: AIDS research and therapy
Published: October 30, 2015
An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life.
Journal: Antimicrobial agents and chemotherapy
Published: October 28, 2009
Showing 1-8 of 8
Last Updated: 09/26/2026